Relebactam

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Relebactam is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2019. DrugCentral lists 6 molecular targets, including KPC-2, bla and blaCTX-M-15. Recorded indications include Complicated Genitourinary Tract Infection, Escherichia coli urinary tract infection, Gastrointestinal infection caused by Klebsiella aerogenes and Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs.

• Approval status: onp (first approved 2019 by the FDA).
• Molecular targets: KPC-2, bla, blaCTX-M-15 and ampC (6 listed in DrugCentral).
• Indications: Complicated Genitourinary Tract Infection, Escherichia coli urinary tract infection, Gastrointestinal infection caused by Klebsiella aerogenes, Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs and Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs and others.
• ATC code: J01DH56 (Carbapenems).
• Molecular formula: C12H20N4O6S; molecular weight 348.37 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (18)

• Complicated Genitourinary Tract Infection
• Escherichia coli urinary tract infection
• Gastrointestinal infection caused by Klebsiella aerogenes
• Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs
• Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs
• Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs
• Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs
• Infection caused by Klebsiella spp resistant to carbapenem antimicrobial drugs
• Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs
• Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs
• Infectious disease of abdomen
• Intestinal infection due to E. coli
• Intestinal infection due to Pseudomonas
• Pseudomonas gastrointestinal tract infection
• Pseudomonas urinary tract infection
• Pyelonephritis
• Urinary tract infection caused by Klebsiella
• Urinary tract infectious disease

Mechanism & targets

Molecular targets (6)

Target	Gene	Action	Activity
Beta-lactamase	KPC-2	inhibitor	IC50 6.64
Beta-lactamase	bla	inhibitor	IC50 6.59
Beta-lactamase	blaCTX-M-15	inhibitor	IC50 6.40
Beta-lactamase	ampC	unknown	IC50 6.33
Beta-lactamase	L2camp	inhibitor	IC50 6.33
Beta-lactamase	blaKPC-4	inhibitor	IC50 6.04

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	MSD K.K.	Yes
2019-06-16	FDA	—	MSD MERCK CO

ATC classification

ATC code	Therapeutic hierarchy
J01DH56	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems

Chemical structure

• Molecular formula: C₁₂H₂₀N₄O₆S
• Molecular weight: 348.37 g/mol
• CAS number: 1174018-99-5
• InChIKey: SMOBCLHAZXOKDQ-ZJUUUORDSA-N
• PubChem CID: 44129647

OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Relebactam used for?

DrugCentral lists the following indications for Relebactam: Complicated Genitourinary Tract Infection, Escherichia coli urinary tract infection, Gastrointestinal infection caused by Klebsiella aerogenes, Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs, Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs, Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs, Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs and Infection caused by Klebsiella spp resistant to carbapenem antimicrobial drugs and others.

How does Relebactam work?

Its molecular targets in DrugCentral include KPC-2 (inhibitor), bla (inhibitor), blaCTX-M-15 (inhibitor) and ampC.

When was Relebactam first approved?

Relebactam was first approved by the FDA in 2019.

What is the chemical formula of Relebactam?

Relebactam has the molecular formula C12H20N4O6S and a molecular weight of 348.37 g/mol.

Sources

• DrugCentral drug card 5342 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3301605 — compound record and bioactivity
• PubChem CID 44129647 — chemical identifiers
• DrugBank DB12377 — drug record
• FDA UNII Y1MYA2UHFL — substance identity
• DailyMed: FDA labels for Relebactam — current prescribing information (label search)

How this page is built: methodology · editorial policy & corrections.